Koro CE, Bowlin SJ, Weiss SR. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.
Pharmacoepidemiol Drug Saf.
Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction.
Jensen BV. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Delea T. Exposure to glitazone antidiabetics and risk of heart failure among person’s with type 2 diabetes: a retrospective population-based cohort analysis. American College of Cardiology 51st Annual Scientific Session. Atlanta, Georgia. March 19, 2002.
Coulter D, Bate A, Meybroom R, et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study.
British Medical Journal
Loke Y, Derry S, Pritchard-Copley A. Appetite suppressants and valvular heart disease—a systematic review.
BMC Clin Pharmacol
Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors
National Institutes of Health website. Available at:
Neuteufl T, Heher S, Kostner K, et al. Contribution of nicotine to acute endothelial dysfunction in long-term smokers.
Journal of the American College of Cardiology.
Substance Abuse and Mental Health Administration website. Available at:
US Department of Health and Human Services website. Available at:
Please be aware that this information is provided to supplement the care
provided by your physician. It is neither intended nor implied to be a
substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER
IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the
advice of your physician or other qualified health provider prior to
starting any new treatment or with any questions you may have regarding a
Copyright © 2007
EBSCO Publishing All rights reserved.